The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
Open accessAbstract
Glucocorticoids (GCs) are the most commonly used antiinflammatory and immunosuppressive drugs. Their outstanding therapeutic effects, however, are often accompanied by severe and sometimes irreversible side effects. For this reason, one goal of research in the GC field is the development of new drugs, which show a reduced side-effect profile while maintaining the antiinflammatory and immunosuppressive properties of classical GCs. GCs affect gene expression by both transactivation and transrepression mechanisms. The antiinflammatory effects are mediated to a major extent via transrepression, while many side effects are due to transactivation. Our aim has been to identify ligands of the GC receptor (GR), which preferentially induce transrepression with little or no transactivating activity. Here we describe a nonsteroidal selective GR-agonist, ZK 216348, which shows a significant dissociation between transrepression and transactivation both in vitro and in vivo. In a murine model of skin inflammation, ZK 216348 showed antiinflammatory activity comparable to prednisolone for both systemic and topical application. A markedly superior side-effect profile was found with regard to increases in blood glucose, spleen involution, and, to a lesser extent, skin atrophy; however, adrenocorticotropic hormone suppression was similar for both compounds. Based on these findings, ZK 216348 should have a lower risk, e.g., for induction of diabetes mellitus. The selective GR agonists therefore represent a promising previously undescribed class of drug candidates with an improved therapeutic index compared to classical GCs. Moreover, they are useful tool compounds for further investigating the mechanisms of GR-mediated effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, novel treatments aimed at improving the benefit/risk ratio of GCs therapy (selective GC receptor agonists, SEGRAs), which are currently being trialed, are unlikely to alter the risk of adrenal insufficiency.”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This is probably because adrenal insufficiency can develop with the same mechanism, mediating the “therapeutic” anti-inflammatory effects of these compounds [36].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
STEROID RECEPTOR REGULATED TRANSCRIPTION OF SPECIFIC GENES AND GENE NETWORKS
Yamamoto, K. R. (1985) · Annual Review of Genetics · doi:10.1146/annurev.ge.19.120185.001233 · Cited by 1,872
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Self-citationSteroid hormone receptors: Many Actors in search of a plot
Beato, M., Herrlich, P., & Schütz, G. (1995) · Cell · doi:10.1016/0092-8674(95)90201-5 · Cited by 1,823
Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms
Barnes, P. J. (1998) · Clinical Science · doi:10.1042/cs0940557 · Cited by 1,591
DNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068
Cole, T. J., Blendy, J. A., Monaghan, A. P., Krieglstein, K., Schmid, W., Aguzzi, A., Fantuzzi, G., Hummler, E., Unsicker, K., & Schütz, G. (1995) · Genes & Development · doi:10.1101/gad.9.13.1608 · Cited by 946
Jantzen, H.-M., Strähle, U., Gloss, B., Stewart, F., Schmid, W., Boshart, M., Miksicek, R., & Schütz, G. (1987) · Cell · doi:10.1016/0092-8674(87)90752-5 · Cited by 724
Heck, S., Kullmann, M., Gast, A., Ponta, H., Rahmsdorf, H. J., Herrlich, P., & Cato, A. C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06726.x · Cited by 522
Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1
Kassel, O. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7108 · Cited by 479
Research works printed but not linked: 6
- Resche-Rigon, M. & Gronemeyer, H. (1998) Curr. Opin. Chem. Biol. 4, 501-507.
- Beato, M., Herrlich, P. & Schütz, G. (1994) Cell 83, 851-857.
- Yoshinuchi, I., Shingu, R., Nakajima, H., Hamaguchi, T., Horikawa, Y., Yamasaki, T., Oue, T., Ono, A., Miyagawa, J. I., Namba, M., et al. (1998) J. Clin. Metab. 83, 1016-1019.
- Carroll, J. J., Smith, N. & Babson, A. L. (1971) Biochem. Med. 2, 171-180.
- Patschan, D, Loddenkemper, K. & Buttgereit, F. (2001) Bone 6, 498-505.
- Anonymous (1999) Drug Ther. Bull. 3, 57-58.
Cited by
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Adverse effects of topical glucocorticosteroids
Hengge, U. R., Ruzicka, T., Schwartz, R. A., & Cork, M. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.01.010 · Cited by 1,151
Fluorine in medicinal chemistry: A review of anti-cancer agents
Isanbor, C., & O’Hagan, D. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2006.01.011 · Cited by 1,120
Nie, J., Guo, H., Cahard, D., & Ma, J. (2010) · Chemical Reviews · doi:10.1021/cr100166a · Cited by 1,088
Glucocorticoid resistance in inflammatory diseases
Barnes, P. J., & Adcock, I. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60326-3 · Cited by 983
Metadata
- Authors
- Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K.
- Affiliations
- Corporate Research Business Area Dermatology, Corporate Project Management Strategic Business Unit Specialized Therapeutics, and Medicinal Chemistry, Schering AG, Berlin, D-13342 Berlin, Germany
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-12-23
- Volume
- 101
- Issue
- 1
- Pages
- 227-232
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC314167
- OpenAlex
- W2043703663
- Cited by
- 466
- References
- 31
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 11 · 2020: 15 · 2019: 20 · 2018: 14 · 2017: 19 · 2016: 18 · 2015: 33 · 2014: 24 · 2013: 22 · 2012: 24
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- glucocorticoid receptor, selective glucocorticoid receptor agonists, transrepression, transcriptional activation, anti-inflammatory activity, skin inflammation, topical corticosteroids, prednisolone, glucocorticoid adverse effects, blood glucose, skin atrophy, diabetes risk, therapeutic index
- MeSH terms
- Animals, Anti-Inflammatory Agents, Benzofurans, Enzyme Induction, Glucocorticoids, Humans, Leukocytes, Mononuclear, Ligands, Prednisolone, Receptors, Glucocorticoid, Recombinant Proteins, Skin, Tumor Necrosis Factor-alpha, Tyrosine Transaminase, Transcriptional Activation, Interleukin-8, Rats, Wistar, Interleukin-12, Protein Subunits, Benzoxazines, Mice, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. https://app.cochat.ai/papers/10.1073/pnas.0300372101
- The paper
- Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004). Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0300372101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.